Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness
NEW YORK, Nov. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p01023648/Downstream-Processing-in-Biopharmaceuticals---Adoption-of-Disposable-Technology-at-Improved-Economies-of-Scale-to-Optimize-Production-Efficiency-and-Cost-effectiveness.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness
Summary
GBI Research, the leading business intelligence provider, has released its latest research, "Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness", which provides key data, information and analysis of the Contract Manufacturing Organization (CMO) industry, and the downstream processing and reagent market. The report provides comprehensive insight into the size of the CMO market, the downstream processing and reagent market and includes forecasts, key reasons for outsourcing, market characterization, downstream process in biopharmaceuticals, major reagents, reagent suppliers and the reagent market related to downstream processing, profiles of key equipment players, key reagent players and key CMO players, drivers and restraints and deals analysis.
This report is built using data and information sourced from proprietary databases, primary and secondary research and uses in-house analysis from GBI Research's team of industry experts.
Major CMOs offer both upstream and downstream manufacturing functions equally. In addition to manufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging, and even marketing. According to industry experts, almost 60% of the CMO market in dominated by manufacturing functions, out of which more than 50% is dominated by the downstream process. GBI research suggests that the CMO market size for downstream processing is set to grow at a Compound Annual Growth Rate (CAGR) of 15.1%, which is more than the growth in the overall CMO biopharmaceutical market.
Scope
- A detailed overview of the downstream processing, CMO industry and reagent market.
- Annualized market data and forecasts for the downstream processing, CMO industry and reagent market.
- A detailed overview of key reasons behind outsourcing, outsourcing service models and key drivers and restraints of the market.
- A detailed discussion of the downstream processing.
- Company profiles of major equipments suppliers, CMOs and reagent players including the key services offered by them and their financial information.
- Analysis of the Merger and Acquisition (M&A) deals involving key companies
Reasons to buy
- Develop market-entry and market expansion strategies by identifying areas for high growth and opportunities.
- Understand the factors shaping the downstream processing, CMO industry and reagent market.
- Identify the top players in the major equipment suppliers, CMO and reagent market, their financial revenues, geographical presence and key services offered.
- Analyze the key geographies that are lucrative markets for the downstream processing and as well as CMOs.
- Analyze the trends in licensing and M&A deals and explore potential investment opportunities
- Understand upcoming trends that are poised to drive the future growth of the downstream processing
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Downstream Processing in Biopharmaceuticals - Introduction 9
3 Downstream Processing in Biopharmaceuticals - Market Overview 10
3.1 Overview of Biopharmaceuticals 10
3.1.1 Cytokines 10
3.1.2 Enzymes 10
3.1.3 Hormones 10
3.1.4 Clotting Factors 10
3.1.5 Vaccines 11
3.1.6 Monoclonal Antibodies 11
3.1.7 Cell Therapies 11
3.1.8 Antisense Drugs 11
3.1.9 Peptide Therapeutics 11
3.2 Overview of Downstream Processing in Biopharmaceuticals 12
3.2.1 A Typical Downstream Processing Operation 13
3.2.2 Major Check Points during Downstream Processing 14
4 Downstream Processing in Biopharmaceuticals - Role of Downstream Processing in the Biopharmaceutical Industry 15
4.1 Major Reagents, Reagent Suppliers and Reagents Market related to Downstream Process 18
4.1.1 Major Reagents 18
4.1.2 Reagent Suppliers 19
4.1.3 Reagent Market 21
4.2 Major Equipment Suppliers 22
5 Downstream Processing in Biopharmaceuticals - Downstream Processing Market for CMOs 24
5.1 Global CMO Market Overview 24
5.2 CMO Biopharmaceuticals Market Characterization 24
5.3 CMO Market Size for Downstream Processing 26
6 Downstream Processing in Biopharmaceuticals - Challenges and Unmet Needs in Downstream Bioprocess 28
6.1 Challenges 28
6.1.1 Chromatographic Capture 28
6.1.2 Reducing the Purification Steps 28
6.1.3 Titer Increment/Capacity Bottleneck 29
6.1.4 Virus Clearances 29
6.1.5 Scaling –Up 29
6.2 Unmet Needs 29
6.2.1 Unmet Medical Needs 29
6.2.2 Realistic Achievement of Economies of Scale 29
6.2.3 Technological Development of Disposables at Large Scale 30
6.2.4 Reagent Costs and their Effectiveness 30
7 Downstream Processing in Biopharmaceuticals - Emerging Technologies and their Implications 31
7.1 Single Use Technology/Disposable Technology 32
7.1.1 Advantages 32
7.1.2 Disadvantages 32
7.2 Multi-column Chromatography 32
7.2.1 Advantages 32
7.2.2 Disadvantages 33
7.3 Tangential Flow Filtration 33
7.3.1 Advantages 33
7.3.2 Disadvantages 33
8 Downstream Processing in Biopharmaceuticals - Industry Analysis 34
8.1 Key Drivers and Restraints 34
8.1.1 Key Drivers of Downstream Processing Market 34
8.1.2 Key Restraints of Downstream Processing Market 35
8.2 Porter's Five Forces Model for Industry Analysis 36
8.3 Major Events and their Impact – Analysis 38
9 Downstream Processing in Biopharmaceuticals - Competitive Landscape 39
9.1 Market Dynamics of Downstream Processing and Impact 39
9.1.1 Market Structure 39
9.2 Key Equipment Players 40
9.2.1 Pall Corporation 40
9.2.2 Millipore 42
9.2.3 Sartorius Stedim Biotech S.A. 44
9.3 Key Reagent Players 46
9.3.1 Life Technologies 46
9.3.2 Sigma Aldrich 48
9.4 Key CMO Players 50
9.4.1 Lonza 50
9.4.2 Boehringer Ingelheim 52
9.4.3 Diosynth Biotechnology 54
10 Downstream Processing in Biopharmaceuticals - Appendix 56
10.1 Market Definitions 56
10.2 Abbreviations 56
10.3 Bibliography 57
10.4 Research Methodology 58
10.4.1 Coverage 58
10.4.2 Secondary Research 58
10.4.3 Primary Research 59
10.4.4 Expert Panel Validation 59
10.5 Contact Us 59
10.6 Disclaimer 59
1.1 List of Tables
Table 1: Downstream Processing, Global, Cost Breakups of Upstream and Downstream Processing, 2011 17
Table 2: Downstream Processing, Global, Reagent Suppliers, 2011 20
Table 3: Downstream Processing, Global, Total Reagent Market for Downstream Processing, Revenue ($m), 2009–2011 22
Table 4: Downstream Processing, Global, Total Reagent Market for Downstream Processing, Revenue Forecast ($m), 2011–2018 22
Table 5: Downstream Processing, Global, Equipment Suppliers, 2011 23
Table 6: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue ($bn), 2008–2011 25
Table 7: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue Forecast ($bn), 2011–2018 25
Table 8: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue ($bn), 2009–2011 27
Table 9: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue ($bn), 2011–2018 27
Table 10: Downstream Processing, Key Equipment Players, Pall Corporation, Major M&A Deals, 2009–2012 41
Table 11: Downstream Processing, Key Equipment Players, EMD Millipore, Major M&A Deals, 2009–2010 43
Table 12: Downstream Processing, Key Equipment Players, Sartorius Stedim Biotech S.A, Major M&A Deals, 2008 45
Table 13: Downstream Processing, Key Reagent Players, Life Technologies, Major M&A Deals, 2009–2011 47
Table 14: Downstream Processing, Key Reagent Players, Sigma-Aldrich, Major M&A Deals, 2009–2012 49
Table 15: Downstream Processing, Key CMO Players, Lonza, Major M&A Deals, 2009–2010 51
Table 16: Downstream Processing, Key CMO Players, Boehringer Ingelhiem, Major M&A Deals, 2009–2011 53
Table 17: Downstream Processing, Key CMO Players, Diosynth Biotechnology, Major M&A Deals, 2009–2011 55
1.2 List of Figures
Figure 1: Downstream Processing, Global, Biopharmaceutical Types, 2011 10
Figure 2: Downstream Processing, Global, Overview of General Drug Development Process, 2011 12
Figure 3: Downstream Processing, Global, Process Steps, 2011 13
Figure 4: Downstream Processing, Global, Changing Distribution of Cost along with Yield Increment, 2011 15
Figure 5: Downstream Processing, Global, Yield Percentage vs Number of Purification Steps, 2011 16
Figure 6: Downstream Processing, Global, Cost Breakups of Upstream and Downstream Processing, 2011 17
Figure 7: Downstream Processing, Global, Total Reagent Market for Downstream Processing, Revenue ($m), 2009–2018 21
Figure 8: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue ($bn), 2008–2018 25
Figure 9: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue ($bn), 2009–2018 26
Figure 10: Downstream Processing, Global, Challenges, 2011 28
Figure 11: Downstream Processing, Global, Emerging Technologies and their Likely Adaptation, 2011 31
Figure 12: Downstream Processing, Global, Industry Analysis, Key Drivers and Restraints, 2011 35
Figure 13: Downstream Processing, Global, Industry Analysis, Porter's Five Forces Model, 2011 36
Figure 14: Downstream Processing, Global, Industry Analysis, Major Market Events and their Impact, 2011 38
Figure 15: Downstream Processing, Global, Industry Analysis, Market Dynamics, 2011 39
Figure 16: Downstream Processing, Key Equipment Players, Business Overview, Pall Corporation, 2011 40
Figure 17: Downstream Processing, Key Equipment Players, Business Overview, EMD Millipore, 2011 42
Figure 18: Downstream Processing, Key Equipment Players, Business Overview, Sartorius Stedim Biotech S.A, 2011 44
Figure 19: Downstream Processing, Key Reagent Players, Business Overview, Life Technologies, 2011 46
Figure 20: Downstream Processing, Key Reagent Players, Business Overview, Sigma-Aldrich, 2011 48
Figure 21: Downstream Processing, Key CMO Players, Business Overview, Lonza, 2011 50
Figure 22: Downstream Processing, Key CMO Players, Business Overview, Boehringer Ingelheim, 2011 52
Figure 23: Downstream Processing, Key CMO Players, Business Overview, Diosynth Biotechnology, 2011 54
Companies Mentioned
Pall Corporation
Millipore
Sartorius Stedim Biotech S.A.
Life Technologies
Sigma Aldrich
Lonza
Boehringer Ingelheim
Diosynth Biotechnology
To order this report:
Biopharmaceutical Industry: Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article